

## Original Article

# A study on the therapeutic effects of autologous platelet-rich plasma in the treatment of limbs refractory wound infection

Zhaohui Chen

*Department of Orthopedics, The First Affiliated Hospital of Henan University, Kaifeng City, Henan Province, China*

Received August 15, 2017; Accepted September 18, 2017; Epub November 15, 2017; Published November 30, 2017

**Abstract:** Objective: To discuss the therapeutic effects of autologous platelet-rich gel (APG) in the treatment of limbs refractory wound infection. Methods: A total of sixty patients with refractory wound infection in lower limb were treated in our hospital from January 2016 to December 2016, who had received one month of wound treatment but unhealed. After random grouping, thirty of them were treated with APG as the treatment group (Group APG), the rest thirty were treated with isotonic saline as the control group (Group Con). The wound areas, pain scores and colony-forming units (CFU) on infected tissue of the patients in the two groups on admission and those at the 7<sup>th</sup> day after treatment, the complications on the 7<sup>th</sup> day after therapy and the follow-up cure time of patients were compared and analyzed. Results: The wound areas in Group APG at the 7<sup>th</sup> day after therapy were evidently declined compared with those on admission ( $P=0.021$ ). At the same time, the wound areas of Group APG were smaller than those of Group Con ( $P=0.035$ ). The wound CFU of two groups were both decreased gradually from the 1<sup>st</sup> to the 7<sup>th</sup> day after treatment (all  $P<0.05$ ). Besides, the decline in Group APG was sharper than in Group Con ( $P=0.003$ ). There was no statistical difference in patients' wound pain scores in two groups. The cure time of Group APG was  $15.2\pm 2.2$  days, while that of Group Con was  $20.2\pm 2.2$  days, and the difference had statistical significance ( $P=0.032$ ). The wound infection rate ( $P<0.001$ ) and scar index ( $P=0.049$ ) of Group APG after treatment were apparently lower than those of Group Con. Conclusion: Autologous platelet-rich gel can decrease wound areas, reduce CFU on wound, shorten the wound cure time and lessen the occurrence of complications.

**Keywords:** Autologous platelet-rich gel, refractory wound infection, lower limb

## Introduction

The refractory infected wound caused by wound infection has increased by years in China and its incidence rate was increased from 48% to 67.5% in 2015 [1, 2]. The traditional treatment for wound infection included debridement, application of negative pressure vacuum extraction, topical application of antibiotics, medicine for promoting epidermis growth, change fresh dressing for a wound, etc. However, all the above treatment measures have relatively little influence on the direct healing process of wound [3, 4].

Refractory wound infection does not threaten patients' life such as sepsis, etc., but the patients with refractory wound infection still need long-term dressing change and antibiotics application, which will then lead to drug

resistance in patients to various strains, thus significantly enhancing the difficulties in wound infection treatment, increasing hospitalization and the expenses [5, 6]. Some patients even suffered from severe complications and sequelae, which could result in a significant decrease in life quality [2]. Consequently, the therapy for refractory wound infection has been an urgent need.

In recent years, autologous platelet-rich gel (APG) has been a research hot spot. It was found that APG was able to repair bone and soft tissue injuries, inhibit the growth of bacterial, reduce wound infection and so forth [7-9]. Therefore, in this study, 60 patients with lower limb refractory wound infection were collected, 30 patients were treated with APG and the rest 30 patients were treated with isotonic saline. Through observing wound areas, all the colony-

## Effects of autologous platelet-rich plasma on wound infection

forming units (CFU) on wound tissue, pain scores of wound, cure time and complications of wound infection of patients, the antibacterial effect and healed-promoting effect for refractory wound infection of APG could be evaluated.

### Materials and methods

This clinical trial was approved by Ethnic Committee with signed informed consent from all the patients.

#### *Cases collecting*

A total of sixty patients with refractory wound infection of lower limb, who had received one-month wound treatment but unhealed, were treated in our hospital from January 2016 to December 2016.

**Inclusion criteria:** Patients who met the diagnosis criteria of refractory wound infection without any sign of improvement after one month of debridement, application of negative pressure vacuum extraction, application of antibiotics, change fresh dressing for a wound, etc.; patients whose wound appeared white skin edge, darkened necrotic tissue, little and atrophic granulation tissue and sometimes accompanied with exposure of skeleton, tendon or muscle tissue; patients aged 18-80 years old; patients who were not treated with APG or other similar therapies before.

**Exclusion criteria:** Patient who had severe cardiac, liver, lung, kidney or other systematic diseases; patient who had generalized infection or severe complications; patients who were pregnant or in lactation; patients without limbs refractory wound infection.

#### *Grouping*

According to random number table, patients were divided into two groups with 30 cases in each: one group was treated with APG (Group APG); the other group were treated with conventional isotonic saline as the control group (Group Con).

#### *Treatment measures*

The wounds of patients in Group APG were covered with APG wet dressings and then totally exposed (change the dressing once per day).

While, the wounds of patients in Group Con were only covered with isotonic saline gauzes and then a half of the wound was exposed (change the dressing once per day).

**Preparation of APG:** The preparation process of APG was carried out in strict accordance with aseptic procedures. The venous blood (40 mL) was collected from every patient, and then put into the 50-mL centrifuge tube with 4 mL of sodium citrate added in advance. After gently shaking, it was centrifuged at 2000 rpm/min for 10 min. All the upper plasma (red blood cells layer) which was 1 mm above the interface was absorbed and transferred to a new centrifuged tube and re-centrifuged at 4000 rpm/min for 10 min. The upper plasma was discarded and the left fluid was the platelet-rich plasma. Next, the platelet-rich plasma was mixed up with 10% CaCl<sub>2</sub> in proportion of 1:9. Finally, APG was obtained by this way and preserved at -20°C [10, 11].

#### *Follow-up*

**Change of wound areas:** Homogeneous paper from CompatDP was applied to cut as shape as the patients' wound and then weighted by the electronic balances with the accuracies of 0.001 g and 0.0001 g respectively. The weight of the wound shape-like paper represented the wound areas, to be more specific, the heavier the wound shape-like papers were, the bigger the wound areas were. Patients' wound areas of both groups were measured respectively at the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>, 5<sup>th</sup>, 6<sup>th</sup>, and 7<sup>th</sup> day after treatment.


**CFU in vitro:** The infection wound tissues were taken respectively at the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>, 5<sup>th</sup>, 6<sup>th</sup>, and 7<sup>th</sup> day after treatment, coated on LB solid medium (10 g/L tryptone, 5 g/L yeast extract and 10 g/L sodium chloride) and incubated in the constant temperature incubator at 37°C for 12 h. Then the CFU was counted, and its everyday means and standard deviations of both groups were calculated [12].

**Wound tissue pain scores:** Both groups of patients' pain scores were evaluated respectively by visual analogue scale on admission and at the 7<sup>th</sup> day after corresponding treatment (0 point means painless, 10 points means extremely painful). The wound tissue pain scores of all patients in two groups were recorded [13].

## Effects of autologous platelet-rich plasma on wound infection

**Table 1.** Patients' general information

Item	Group APG (n=30)	Group Con (n=30)	P value
Male/female	25/5	20/10	0.136
Age	45.5±5.6	48.1±8.2	0.674
Primary diseases			
Tibial and fibular fracture	7	8	0.766
Calcaneus fracture	5	10	0.136
Lower limb open fracture	9	6	0.371
Tibia osteomyelitis	2	3	0.640
Femur osteomyelitis	3	2	0.640
Infection after foot orthopedic surgery	4	1	0.161
Diabetes	3	2	0.640



**Figure 1.** Comparison of patients' wound areas on admission and at the 7<sup>th</sup> day after the treatment in two groups. \* $P < 0.05$  (the 1<sup>st</sup> day vs. the 7<sup>th</sup> day after the treatment of Group APG); # $P < 0.05$  (Group APG vs. Group Con at the 7<sup>th</sup> day after the treatment); CON, Group Con; APG, Group APG.

**Cure time and complications:** All the patients were admitted to our hospital for return visits or therapies at the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> and 4<sup>th</sup> month in accordance with prior agreement. All patients' cure time, wound infection rate, scar index, joint deformity and other complications were recorded.

### Observation indexes

Primary observation indexes: Wound areas, CFU count and wound pain scores. Secondary observation indexes: Wound cure time, complications of wound infection.

### Statistical analysis

All measurement data were expressed as mean  $\pm$  standard deviation (mean  $\pm$  sd), and analyzed by SPSS 17.0 software package. The difference value before and after the treatment as well as the baseline before treatment and the value after treatment between groups were compared by one-way ANOVA. Comparison of the

data before and after the treatment within group was conducted by paired t test. Comparison of two groups of patients' wound CFU in 7 days after treatment at multiple time points were underwent by repeated measures ANOVA, combined with Bonferroni correction. Comparison of complications between two groups was conducted by t test. GraphPad Prism 5.0 was applied for analysis and mapping of all the graphs. Inspection level:  $\alpha = 0.05$ . When  $P <$

0.05, the difference was statistically significant.

## Results

### Patients' general information on admission

There was no statistical difference in patients' sex ratio, age and primary diseases (**Table 1**). Patients' primary diseases included 15 cases of tibial and fibular fractures, 15 cases of calcaneus fractures, 15 cases of lower limb open fractures, 5 cases of tibia osteomyelitis, 5 cases of femur osteomyelitis, 5 cases of infection after foot orthopedic surgeries and 5 cases of diabetes.


### Comparison of patients' wound areas on admission and at the 7<sup>th</sup> day after the treatment in two groups

Among the patients with limbs refractory wound infection, those in Group APG had an obvious decline in wound areas at the 7<sup>th</sup> day after the treatment. Compared with those on admission, this difference had statistical significance ( $P = 0.021$ ). At the meantime, wound areas of patients in Group APG at the 7<sup>th</sup> day after the treatment were apparently less than those in Group Con ( $P = 0.035$ ). As for Group Con, there was no statistical significance in wound areas between on admission and at the 7<sup>th</sup> day after the treatment ( $P = 0.082$ ). See **Figure 1**.


### Comparison of patients' 7-day wound CFU after the treatment in two groups

Among the patients with limbs refractory wound infection, their wound CFU in Group APG and Group Con both gradually reduced from the 1<sup>st</sup>


## Effects of autologous platelet-rich plasma on wound infection



**Figure 2.** Comparison of patients' 7-day wound CFU after the treatment in two groups. \* $P < 0.05$  (comparison of the 7<sup>th</sup> and 1<sup>st</sup> day after treatments of Group APG and Group Con); # $P < 0.05$  (comparison between Group APG and Group Con after the treatment); CON, Group Con; APG, Group APG.



**Figure 3.** Comparison of patients' wound pain scores between on admission and at the 7<sup>th</sup> day after the treatment. CON, Group Con; APG, Group APG.



**Figure 4.** Comparison of patients' cure time in two groups. CON, Group Con; APG, Group APG; \* $P < 0.05$ , the cure time of two groups was statistically different.

to 7<sup>th</sup> day after their corresponding treatments (all  $P < 0.001$ ). Moreover, the decline of Group APG was sharper than that of Group Con ( $P = 0.003$ ). Compared with the 1<sup>st</sup> day after the treatment in Group APG, wound CFU was clearly lessened at the 7<sup>th</sup> day after the treatment ( $P < 0.001$ ). The comparison of patients' wound

CFU at the 7<sup>th</sup> day after the treatment in two groups indicated that the wound CFU count of Group APG was much less than that of Group Con ( $P = 0.003$ ). There was no statistical difference in wound CFU at the 1<sup>st</sup> and 2<sup>nd</sup> after the treatment in both groups ( $P = 0.812, 0.634$ ). See **Figure 2**.

### *Comparison of patients' wound pain scores between on admission and at the 7<sup>th</sup> day after the treatment*

There was no statistical difference in patients' wound pain scores between on admission and at the 7<sup>th</sup> day after the treatment in Group APG ( $P = 0.936$ ) and in Group Con ( $P = 0.90$ ). As for the change of patients' wound pain scores before and after treatment, there was no statistical difference between Group APG and Group Con ( $P = 0.892$ ). See **Figure 3**.

### *Comparison of patients' cure time in two groups*

Four-month follow-up was carried out for patients in both groups without any missing. All the patients were admitted to our hospital as agreed before at the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> and 4<sup>th</sup> month after treatment for return visits or therapies and the patients' cure time was recorded. The cure time of Group APG was  $15.2 \pm 2.2$  days, while that of Group Con was  $20.2 \pm 2.2$  days. So, the cure time of Group APG was apparently shorter than that of Group Con and the difference was statistically significant ( $P = 0.032$ ). See **Figure 4**.

### *Comparison of patients' complications in two groups*

All the sixty patients included in this clinical research finished the four-month follow-up without any missing. And all of them had return visits or therapies at the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> and 4<sup>th</sup> month after discharge. Consequently, their complications, wound infection rate, scar index and joint deformity were recorded. The results showed that both the wound infection rates and scar indexes of Group APG were obviously lower than those of Group Con and the differences were statistical ( $P < 0.05$ ). Nevertheless, the incidences of joint deformity of both groups were lower and there was no statistical difference (**Table 2**).

## Effects of autologous platelet-rich plasma on wound infection

**Table 2.** Complications of patients in two groups

	Group APG	Group Con	t value	P value
Infection rate	3.4±0.5	20.4±2.3	-12.51	0.000
Scar index	4.6±1.5	9.3±2.5	-2.792	0.049
Joint deformity	1.3±0.2	1.6±0.2	-1.837	0.140

### Discussion

APG is a kind of concentrated platelet gel obtained from two rounds of centrifugation of autologous blood, and the massive concentrated platelet can release a great quantity of growth factors after activation, such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor- $\beta$  (TGF- $\beta$ ), vascular endothelial cell growth factor (VEGF) and so forth [14]. Through chemotaxis, constriction of blood vessels and inducing the proliferation of epithelial and endothelial cells, PDGF can regulate wound repair by secretion of TGF- $\beta$  [15].

EGF is a kind of cell division promoting factor. On the one hand, it can stimulate the proliferation and differentiation of collagenocyte, and facilitate the re-epithelialization of wounds. On the other hand, it can promote the formation of blood vessels [15]. VEGF is a kind of platelet-derived factor, which can stimulate the regeneration of vascular endothelial cell and the formation of cell-extracellular matrix, to accelerate the repair of wounds [16].

In this study, the APG prepared by centrifugation was used in the treatment of limbs refractory wound infection. Compared with the Group Con, APG could obviously lessen the infected wound areas. Chen et al. discovered that APG could significantly speed up the wound cure process of children's facial second degree burn and shorten the cure time [10]. This finding was consistent with our study, which indicated that APG might facilitate the wound cure through the above growth factors.

This experiment found that the APG used in the treatment of refractory wound infection could reduce the CFU on infected wounds and accelerate wound cure. It was in line with Yang's finding that APG was able to inhibit the reproduction of staphylococcus aureus and thus reducing wound infection rates [17]. The high concentrations of platelet and white blood cell

in APG were the key to exert its antibacterial effects. The white blood cells, such as neutrophil, mononuclear, macrophage, etc., play vital roles in innate immune response, antimicrobial immune response and other defense responses. The platelet could activate a large number of growth factors that could constitute a complex regulatory network, which could not only accelerated wound tissue repair but also enhanced local anti-inflammatory ability. Bielecki et al. held the view that after the APG were released, there would be massive antibacterial, anti-inflammatory substances and other metabolites like superoxide. They could directly kill bacteria and accelerate other immune cells to indirectly kill bacteria [18]. As a result, APG could play a better role in preventing infection [19].

APG is an effective autologous component with low incidence of immune rejection. In the absence of external infection sources, the incidence of blood borne disease was extremely low [20]. At the same time, APG is concentrated from the platelet, so it can promote the adhesion of transplanted heterogeneous acellular dermal matrix and the wound base, avoid sliding, eliminate partial cavity and reduce infection with a hemostatic effect [21]. Kim et al. reported that one patient suffered obvious pain and swelling after APG treatment in his study, but the above symptoms disappeared two days later. However, there was no any discomfort occurring to other patients [22]. During the four-month follow-up, our study found that patients treated with APG had apparently less complications compared with the Group Con. Nevertheless, we should also pay attention to the adverse reactions such as the pain and swelling on the wound site. Once the adverse reaction occurred, the treatment must be terminated and the corresponding measures need to be taken to recover the local infected wounds and restore systemic functions.

There were a few limitations in our study. Firstly, as the requirements for APG preparation are very strict, and the platelet can be activated easily, which may lead to the failure of the preparation. It is a waste of autologous blood and the energy of the experimenter. Secondly, perhaps the purity of the prepared APG is not high enough to achieve the satisfying therapeutic effects for some patients. Thirdly, the sample

## Effects of autologous platelet-rich plasma on wound infection

size of this study was limited, so a further experiment with a larger sample size will be carried on later to enhance the credibility.

In conclusion, autologous platelet-rich gel can decrease wound areas, reduce CFU on wound, shorten the wound cure time and lessen the occurrence of complications, which is worth of a dissemination trail in clinic.

### Disclosure of conflict of interest

None.

**Address correspondence to:** Zhaohui Chen, Department of Orthopedics, The First Affiliated Hospital of Henan University, No.357 Ximen Street, Kaifeng City, 475000 Henan Province, China. Tel: +86-0371-22731671; Fax: +86-0371-22731671; E-mail: zhaohuichen321@163.com

### References

- [1] Damaso D, Moreno-Lopez M, Martinez-Beltran J and Garcia-Iglesias MC. Preliminary clinical trial with amikacin in chronic recurrent gram-negative bacterial infections refractory to other antimicrobial agents. *J Infect Dis* 1976; 134 Suppl: S381-383.
- [2] Liu MY. Clinical effect of bacterial lysates in the treatment of elderly patients with bronchial asthma with repeated respiratory infection. *China Modern Medicine* 2015; 121-122.
- [3] Roux D, Danilchanka O, Guillard T, Cattoir V, Aschard H, Fu Y, Angoulvant F, Messika J, Ricard JD, Mekalanos JJ, Lory S, Pier GB and Skurnik D. Fitness cost of antibiotic susceptibility during bacterial infection. *Sci Transl Med* 2015; 7: 297ra114.
- [4] Tandon P, Abbralde JG, Keough A, Bastiampillai R, Jayakumar S, Carbonneau M, Wong E, Kao D, Bain VG and Ma M. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics. *Clin Gastroenterol Hepatol* 2015; 13: 1189-1196, e1182.
- [5] Bessa LJ, Fazii P, Di Giulio M and Cellini L. Bacterial isolates from infected wounds and their antibiotic susceptibility pattern: some remarks about wound infection. *Int Wound J* 2015; 12: 47-52.
- [6] Brown K, Valenta K, Fisman D, Simor A and Daneman N. Hospital ward antibiotic prescribing and the risks of clostridium difficile infection. *JAMA Intern Med* 2015; 175: 626-633.
- [7] Li L, Chen D, Wang C, Yuan N, Wang Y, He L, Yang Y, Chen L, Liu G, Li X and Ran X. Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: a prospective, randomized clinical trial. *Wound Repair Regen* 2015; 23: 495-505.
- [8] Ai ZH, Wan Y, Liu JJ, Lang HM, Xiao J, Li NN, Cheng Y and You ZQ. Therapeutic effect of autologous platelet-rich gel in the treatment of chronic skin ulcer with tophus. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2015; 46: 770-772.
- [9] Carducci M, Bozzetti M, Spezia M, Ripamonti G and Saglietti G. Treatment of a refractory skin ulcer using punch graft and autologous platelet-Rich plasma. *Case Rep Dermatol Med* 2016; 2016: 7685939.
- [10] Chen FL, Li HM and Han LS. Autologous platelet-rich gel for the repair of facial burn wounds of degree II in children. *Journal of Clinical Rehabilitative Tissue Engineering Research* 2011; 15: 6453-6456.
- [11] Pietrzak WS and Eppley BL. Platelet rich plasma: biology and new technology. *J Craniofac Surg* 2005; 16: 1043-1054.
- [12] Cankorur-Cetinkaya A, Dias JML, Kludas J, Slater NKH, Rousu J, Oliver SG, Dikicioglu D. CamOptimus: a tool for exploiting complex adaptive evolution to optimize experiments and processes in biotechnology. *Microbiology* 2017; 163: 829-839
- [13] Breivik H. Fifty years on the visual analogue scale (VAS) for pain-intensity is still good for acute pain. But multidimensional assessment is needed for chronic pain. *Scand J Pain* 2016; 11: 150-152.
- [14] Afshari M, Larijani B, Fadayee M, Ghahary A, Pajouhi M, Bastanhagh MH, Baradar-Jalili R, Vassigh AR and Darvishzadeh F. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. *Therapy* 2005; 2: 759-765.
- [15] Ojalvo AG, Acosta JB, Mari YM, Mayola MF, Perez CV, Gutierrez WS, Marichal, II, Seijas EA, Kautzman AM, Pacheco AE and Armstrong DG. Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction. *Int Wound J* 2017; 14: 214-225.
- [16] Jia-Ming S and Zhang HQ. Biological effects of co-transfection of TGFβ<sub>1</sub> and VEGF mediated by AAVon promoting healing of the cutaneous ulcer in diabetes mellitus. *Journal of Traumatic Surgery* 2007.
- [17] Yang YZ, Liu HC, Liu GJ and Ran XW. antibacterial effect of autologous platelet-rich gel derived from health volunteers in vitro. *Chinese Journal of Reparative and Reconstructive Surgery* 2010; 571-576.
- [18] Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Krol W and Wielkoszynski T. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an

## Effects of autologous platelet-rich plasma on wound infection

- in vitro study. *J Bone Joint Surg Br* 2007; 89: 417-420.
- [19] Chen L, Wang C, Liu H, Liu G and Ran X. Antibacterial effect of autologous platelet-rich gel derived from subjects with diabetic dermal ulcers in vitro. *J Diabetes Res* 2013; 2013: 269527.
- [20] Wu X, Ren J, Luan J, Yao G and Li J. Biochemical, mechanical, and morphological properties of a completely autologous platelet-rich wound sealant. *Blood Coagul Fibrinolysis* 2012; 23: 290-295.
- [21] Napolitano M, Matera S, Bossio M, Crescibene A, Costabile E, Almolla J, Almolla H, Togo F, Giannuzzi C and Guido G. Autologous platelet gel for tissue regeneration in degenerative disorders of the knee. *Blood Transfus* 2012; 10: 72-77.
- [22] Kim E and Lee JH. Autologous platelet-rich plasma versus dextrose prolotherapy for the treatment of chronic recalcitrant plantar fasciitis. *PM R* 2014; 6: 152-158.